CLS Cheat Sheet 2026

The 30 highest-yield CLS facts, distilled from real exam questions. Print it, save it as a PDF, or study it here — free, no sign-up.

1. Why is weight management important in cardiovascular care? → It supports cardiovascular health
2. What is the expected LDL-C reduction with ezetimibe monotherapy? → 15–25%
3. In patients with HIV on antiretroviral therapy, which statin is preferred due to minimal interaction with protease inhibitors? → Pravastatin or rosuvastatin
4. What is the goal of antihypertensive therapy in cardiovascular risk? → Reduce stroke and heart attack risk
5. What is a key principle of secondary causes of dyslipidemia in Clinical Lipid Specialist Certification practice? → Applying structured methodologies based on evidence and best practices
6. How should CLS professionals measure success in novel lipid-lowering therapies? → Using defined metrics, benchmarks, and regular evaluation against established goals
7. What challenge is most commonly encountered in secondary causes of dyslipidemia within Clinical Lipid Specialist Certification practice? → Resistance to change and difficulty maintaining consistency across stakeholders
8. Which genetic disorder is characterized by the accumulation of IDL and causes both hypercholesterolemia and hypertriglyceridemia with palmar xanthomas? → Type III hyperlipoproteinemia (familial dysbetalipoproteinemia)
9. Which condition is a major contributor to cardiovascular risk? → Diabetes mellitus
10. What is the relationship between pediatric lipid disorders and overall Clinical Lipid Specialist Certification professional competency? → It is an essential component that strengthens the overall competency framework
11. Lipoprotein lipase (LPL) deficiency most commonly presents with which triglyceride phenotype? → Type I hyperlipoproteinemia with massive chylomicronemia
12. In patients with type 1 diabetes, what lipid abnormality is most commonly seen when diabetes is well-controlled? → Near-normal lipid profiles, as insulin facilitates lipid metabolism
13. What is the primary lipid effect of prescription omega-3 fatty acids at 4 g/day? → Primarily reduce triglycerides by 25–50%
14. What is a key principle of novel lipid-lowering therapies in Clinical Lipid Specialist Certification practice? → Applying structured methodologies based on evidence and best practices
15. What is the mechanism of action for ezetimibe? → Blocks cholesterol absorption
16. In patients with non-alcoholic fatty liver disease (NAFLD), which statement best describes statin use? → Statins are safe and may even benefit liver histology in NAFLD patients
17. Which diet is known to improve lipid profiles? → Mediterranean diet
18. How does statin therapy & pharmacology contribute to professional excellence in CLS certification? → It enhances competency, improves outcomes, and supports continuous professional growth
19. What is a key principle of patient education & adherence in Clinical Lipid Specialist Certification practice? → Applying structured methodologies based on evidence and best practices
20. In patients with metabolic syndrome, which lipid triad is characteristically found? → Elevated triglycerides, low HDL-C, and increased small dense LDL particles
21. What is the ideal LDL cholesterol level for high-risk individuals? → Below 70 mg/dL
22. What does HDL cholesterol help with? → Cholesterol removal
23. In patients with chronic kidney disease (CKD) stages 3–5 not on dialysis, which lipid-lowering therapy is recommended by KDIGO guidelines? → Statin or statin/ezetimibe combination
24. What blood test is essential for diagnosing dyslipidemia? → Lipid panel
25. Which dietary modification has the greatest impact on reducing severely elevated triglyceride levels? → Restricting total dietary fat intake
26. Which type of lipoprotein is considered atherogenic? → LDL
27. Fenofibrate requires dose adjustment or avoidance in patients with which condition? → Chronic kidney disease or renal impairment
28. For which lipid abnormality are fibrates considered first-line pharmacotherapy? → Severe hypertriglyceridemia (≥500 mg/dL)
29. The triglyceride-to-HDL ratio is used clinically as a surrogate marker for which metabolic condition? → Insulin resistance and small dense LDL particle predominance
30. How should CLS professionals measure success in lipid panel interpretation? → Using defined metrics, benchmarks, and regular evaluation against established goals